research SYSTEMATIC REVIEW OF PHARMACOTHERAPY STRATEGIES IN THE MANAGEMENT OF HIDRADENITIS SUPPURATIVA
Biologic agents are effective for severe hidradenitis suppurativa when other treatments fail.
Search
for
Sort by
Research
30-60 / 1000+ results 
research Understanding the evolving treatment landscape of hidradenitis suppurativa: An analysis of All of Us
Improving access to hidradenitis suppurativa care can reduce social disparities.
research Meta-Analysis of Gene Expression Reveals the Core Transcriptomic Profile of Lesional Scalp in Alopecia Areata
Alopecia areata involves specific gene changes and immune pathways, offering new treatment targets.
research Advances in dermatology research: A comprehensive literature review
Ongoing research and innovation are crucial for improving skin care and treatment.
research IL-33 Contributes to the Pathological Changes of Hair Follicles in Psoriasis: A Potential Target for Psoriatic Alopecia
IL-33 is linked to hair follicle damage in psoriasis and could be a treatment target for hair loss in this condition.
research VIII International Conference "Interdisciplinary aspects of diseases of the skin and mucous membranes" 11-12th March 2022
Higher IL-31 levels are linked to worse itching in chronic kidney disease patients.
research Index
The document is a detailed guide on skin conditions and treatments for dermatologists.
research การศึกษาแบบสุ่มแบ่งครึ่งข้างเพื่อเปรียบเทียบประสิทธิภาพการฉีดโบทูลินัมทอกซินชนิดเอกับ 0.9% โซเดียมคลอไรด์ในผื่นสะเก็ดเงินบนศีรษะ
Botulinum toxin type A significantly reduces scalp psoriasis severity compared to placebo.
research Subject Index
The document lists various dermatology topics, treatments, and diagnostic methods.
research Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases
Ixekizumab has known and some unexpected side effects.
research Ophiasis Alopecia Areata in a Patient With Spondyloarthritis on Secukinumab: A Case Report and Review of the Literature
Secukinumab can cause hair loss, which may improve after stopping the medication.
research Psoriatic Alopecia and Paradoxical Psoriasis Induced by Adalimumab Successfully Treated with Certolizumab: Clinical, Trichoscopic, and in vivo Reflectance Confocal Microscopy Features
Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
research FRI0310 Achievement of low disease activity in lupus patients treated with belimumab is independent of serologic status at baseline: a real-life observational study
Belimumab effectively reduces disease activity in lupus patients, regardless of initial serologic status.
research Poster Presentations
Ustekinumab successfully treated a man's resistant skin condition when other treatments failed.
research P718 Observational real-world evidence on the efficacy and safety of Janus Kinase inhibitors (JAKi) in the treatment of moderate to severe Active Ulcerative Colitis (UC)
Janus Kinase inhibitors are effective and have an acceptable safety profile for treating moderate to severe Ulcerative Colitis.
research 0480 Upadacitinib monotherapy for treatment of pyoderma gangrenosum: A case series
Upadacitinib effectively treats pyoderma gangrenosum.
research Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.
research Tofacitinib for the Treatment of Three Immune-mediated Conditions in One Patient: Ulcerative Colitis, Pyoderma Gangrenosum, and Alopecia Areata
Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.
research A case of recalcitrant pediatric Vogt-Koyanagi-Harada disease successfully controlled with adalimumab
Adalimumab helped control a child's severe eye disease when other treatments failed.
research Effective use of ustekinumab in a patient with concomitant psoriasis, vitiligo, and alopecia areata
Ustekinumab significantly improved psoriasis, vitiligo, and alopecia areata in a patient.
research The Janus kinase 1 inhibitor abrocitinib for the treatment of oral lichen planus
research Paradoxical Skin Reaction to Certolizumab, an Overlap of Pyoderma Gangrenosum and Psoriasis in a Young Woman Treated for Ankylosing Spondylitis: Case Report with Literature Review
A young woman had a rare skin reaction to a medication for her joint disease, and a combination therapy improved her condition.
research 496 Understanding the mechanism of action of secukinumab using lesional hidradenitis suppurativa skin organ culture
Secukinumab reduces immune activity in hidradenitis suppurativa skin.
research AB0442 Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort
Belimumab effectively controls SLE disease activity and reduces steroid use.
research Combination of secukinumab and acitretin for generalized pustular psoriasis: A case report and review of literature
Secukinumab and acitretin together may quickly and effectively treat severe generalized pustular psoriasis.
research Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Adalimumab significantly improved Hidradenitis Suppurativa and quality of life in two patients.
research Low disease activity—irrespective of serologic status at baseline—associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study
Belimumab reduces disease activity, steroid use, and flares in lupus patients.
research First two cases of alopecia areata during golimumab therapy
Membership in a self-help organization is linked to being better informed and having a higher education, but it doesn't clearly affect disease outcomes.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research 050 Evaluation of 3 month data for the use of erenumab for chronic migraine in Glasgow
Erenumab significantly reduced migraine days or severity in most patients after 3 months.